Blog

How can pharma shape itself to be ready to work with PCNs?

The need to offer efficiencies to the NHS creates an opportunity for pharma companies. But to be able to understand where those opportunities lie, they need to identify key networks – and the decision makers within each PCN. Here’s how Inspiremed can help.

The launch of NHS Primary Care Networks in spring 2020 could have a significant effect on pharma companies. The new networks are forming to improve the ability of practices to:

  • recruit and retain staff
  • manage financial and estates pressures
  • provide a wider range of services to patients
  • more easily integrate with the wider health and care system

(The King’s Fund)

The need to offer efficiencies to the NHS creates an opportunity for pharma companies. But to be able to understand where those opportunities lie, they need to identify the key drivers within each Primary Care Network – and build effective market access plans around these key PCNs.

As Primary Care Networks need to offer an improved local service, so pharma companies need to be able to identify the priority areas for each Primary Care Network, for example a specialism in diabetes care or osteoporotic care.

Pharma companies need to consider how they address the new breed of specialist ‘decision-makers’ within PCNs, and how they can influence these key personnel, by offering ‘value’ for the whole group.

Inspiremed can help pharma companies to gain market access by mapping and segmenting PCNs into usable analytics that provide knowledge of and insight into the most potentially valuable groupings for their particular business.

Identifying each PCN’s priorities will be paramount to pharma’s success in developing good and effective market access strategy and campaigns.

How can Inspiremed help Pharma?

Mapping the key PCNs into market access analytics and segmentation models gives direct insight into how these groups are structured across CCGs – and will enable pharma to derive definitive strategies.

Our analytics can quickly help pharma with market access dynamics for this important and evolving NHS group.

My favourite feature? The market share data and territory growth or decline. The RXA tool really allows a company to fine tune their sales strategies and focus on the more profitable accounts. It allows you to target accounts for quick wins and get a good picture of what your competitor’s focuses and successes are.

National Sales Manager, UK Pharmaceutical Company

At a CCG level we can show our customers how we can work with individual surgeries to get substantial cost savings and utilise their budgets better. We work with medicines management teams to help them to save money whilst also improving outcomes.

Country Manager UK, Leading Diagnostics Company

Obviously I wouldn’t recommend Rx Analyser to our direct competitors as I believe the level of insight provided really gives us an edge.

Sales and Marketing Manager, Leading Healthcare Company, 2016

Rx Analyser is used for territory planning, customer proposals, segmentation/targeting positioning, case studies demonstrating the benefits of working alongside us to drive formulary compliance, customer savings analysis and in the future reporting.

Sales and Marketing Manager, Leading Healthcare Company, 2016

I use the data from RXA Budget Impact Model daily. It is the core of everything we do! I cannot recommend the model more. It has had a substantial impact on our business across the board and I would not be without it.

Country Manager UK, Leading Diagnostics Company

Fantastic customer service, any requests from us to fine tune the functionality or appearance of the product is done in most cases on the same day as the request.

National Sales Manager, UK Pharmaceutical Company

Sign up for added insights